logo

Outlook Therapeutics, Inc. (OTLK)



Trade OTLK now with
  Date
  Headline
7/7/2020 8:08:14 AM Outlook Therapeutics Completes Patient Enrollment In NORSE 2 Clinical Trial For ONS-5010 / LYTENAVA
6/17/2020 8:12:42 AM Outlook Therapeutics Provides Clinical Update On ONS-5010 / LYTENAVA
4/14/2020 8:25:46 AM Outlook Therapeutics Provides COVID-19 Impact Update On Impact Of The COVID-19 Pandemic On Status Of NORSE 1 And NORSE 2
2/24/2020 8:07:16 AM Outlook Therapeutics Reports $10.2 Mln Financings Priced At-The-Market
1/28/2020 8:22:22 AM Outlook Therapeutics Enters Agreements With BioLexis
12/26/2019 8:04:47 AM Outlook Therapeutics Completes Previously Announced Warrant Restructuring
12/19/2019 8:13:16 AM Outlook Therapeutics FY Net Loss Attributable $36.0 Mln Or $1.98 Per Share
8/20/2019 8:06:54 AM Outlook Therapeutics Completes Patient Enrollment For NORSE 1 A Phase 3 Clinical Trial For ONS-5010 In Wet AMD
7/16/2019 8:17:05 AM Outlook Therapeutics Doses First Patient In ONS-5010-002 Phase 3 Clinical Trial
4/10/2019 9:13:18 AM Outlook Therapeutics Prices Public Offering Of 10.34 Mln Common Shares